Clofibrate (CPIB), an antihyperlipidemic agent, was employed as a drug response modulator in this study to evaluate its action, if any, on adriamycin (ADR) cytotoxicity in adriamycin insensitive chronic myeloid leukemia (CML) cells in vitro. Inhibition of (3H)-thymidine incorporation was used as a measure of DNA biosynthesis inhibition. A marginally toxic concentration of CPIB [0.001 % (v/v)] was utilized to evaluate the cytotoxicity in CML cells exposed to ADR 5 and 10 μg/ml. A heterogeneous response was observed in 16 different CML blood samples, 9 samples displaying a synergistic, 3 an additive and 4 a less than additive inhibition of DNA biosynthesis when exposed to the combination of ADR and CPIB. The cytotoxic effect induced by ADR alone and in combination with CPIB was found to be irreversible. The data suggest that the cell membrane modulating drug CPIB is effective as an adjuvant to enhance the antiproliferative action of ADR.
BrownF., KleinM., KandaswamyT., MandleH.: Rapid membrane filtration technique for studying the action of 6-thioguanine on tumor cells in vitro. Cancer Res., 23: 254–259, 1963.
3.
BurnsC.P., NorthJ.A.: Adriamycin transport and sensitivity in fatty acid modified leukemia cells. Biochim. Biophys. Acta, 888: 10–17, 1986.
4.
ChitnisM.P., SatyamoorthyK., PradhanS.G., AdvaniS.H.: Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant Sintamil. Oncology, 45: 292–296, 1988.
5.
ChitnisM.P., ParekhH.K., SatyamoorthyK.: Differential effect of Clofibrate on adriamycin cytotoxicity in P388 murine leukemia cells sensitive and resistant to adriamycin. Tumori, 75: 100–105, 1989.
6.
FosterB.J., GrotzingerK.R., McKoyW.M., RubinsteinL.V., HamiltonT.C.: Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother. Pharmacol., 22: 147–152, 1988.
7.
GoldJ.: Potentiation by Clofibrate of in-vivo tumor inhibition by hydrazine sulphate and cytotoxic agents in Walker 256 carcinosarcoma. Cancer Biochem. Biophys., 3: 41–45, 1978.
8.
GuffyM.M., NorthJ.A., BurnsC.P.: Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res., 44: 1863–1866, 1984.
9.
GustafsonA.: Clofibrate and related compounds in hyperlipoproteinaemia - A review. Postgrad. Med. J., 51(suppl. 8): 66–71, 1975.
10.
IchihashiH., KandoT., SakakibaraS., AkiyamaS., WatanabeT.: Application of radioactive precursors for the evaluation of sensitivity of cancer cells to anticancer drugs. Oncology, 41: 88–95, 1984.
11.
JohnsonR.K., ChitnisM.P., EmbreyW.M., GregoryE.B.: In vivo characteristics of resistance and cross-resistance of adriamycin resistant subline of P388 leukemia. Cancer Treat. Rep., 62: 1535–1547, 1978.
12.
LijlstraJ.G., de VriesE.G.F., Mus KietF.A.J., MartiniI.A., BosschaH.T., MulderN.H.: Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int. I. Cancer, 40: 850–856, 1987.
13.
McGrathT., CenterM.S.: Mechanisms of multidrug resistance in HL60 cells: Evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res., 48: 3959–3963, 1988.
14.
NaitoK., SkogS., TribukaitB., AndersonL., HisazumiH.: Cell cycle related (3H)-thymidine uptake and its significance for incorporation into DNA. Cell Tissue Kinet., 20: 447–457, 1987.
15.
NakagawaM., IshiharaN., ShimokawaT., KojimaS.: Effect of Clofibrate on lipid peroxidation in rats treated with aspirin and 4-pentenoic acid. J. Biochem., 101: 81–88, 1987.
16.
PradhanS.G., BasrurV.S., ChitnisM.P., AdvaniS.H.: In vitro enhancement of adriamycin cytotoxicity in human myeloid leukemia cells exposed to verapamil. Oncology, 41: 406–408, 1984.
17.
RamuA., GlaubigerD., McGrathL.T., JoshiA.: Plasma membrane lipid structural order in doxorubicin-sensitive and resistant P388 cells. Cancer Res., 43: 5533–5537, 1983.
18.
RamuA., GlaubigerD., WeintraubH.: Differences in lipid composition of doxorubicin-sensitive and resistant P388 cells. Cancer Treat. Rep., 68: 637–641, 1984.
19.
ShiftmanF.J., FisherJ.M.: Potentiation of chlorambucil activity by serum displacing agents. Proc. Amer. Assoc. Cancer Res., 18: 38–42, 1977.
20.
SehestedM., SkovsgardT., Van DeursB., WinthernielsenH.: Increase in non-specific adsorptive endocytosis in anthracycline and vinca alkaloid resistant Ehrlich ascites tumor cell lines. J. Natl. Cancer Inst., 78: 171–178, 1987.
21.
ShiraishiN., AkiyamaS.I., KobayashiM., KuwanoM.: Lysomotropic agents reverse multiple drug resistance in human cancer cells. Cancer Lett., 30: 251, 1986.
22.
SondakV.K., BertelsenC.A., TanigawaN., Hildebrand ZankiS.U., MortenD.L., KornE.L., KernD.H.: Clinical correlation with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res., 44: 1725–1728, 1984.
23.
ValerioteF., LinH.S.: Synergistic interaction of anticancer agents: A cellular perspective. Cancer Chemother. Rep., 59: 895–899, 1975.
24.
WeisenthalL.M., LippmanM.E.: Clonogenic and non-clonogenic in vitro chemosensitivity assays. Cancer Treat. Rep., 69: 615–632, 1985.
25.
YoungR.C., OzolsR.C., MyersC.E.: The anthracycline antineoplastic drugs. N. Engl. J. Med., 305: 139–153, 1981.
26.
ZaffaroniN., SilvestriniR., SanifilippoO., DaidoneM.G., GaspariniG.: In vitro activity of alkylating agents on human tumors as measured by a short-term antimetabolic assay. Tumori, 71: 555–561, 1985.
27.
ZamoraJ.M., BeckW.T.: Chloroquine enhancement of anti-cancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem. Pharmacol., 35: 4303–4308, 1986.
